Butterfly Network, a digital health firm with the goal of universal access to superior medical imaging, has appointed Dr. Todd M. Fruchterman, M.D., Ph.D. president and CEO, effective February 1^st. Dr. Fruchterman spent nearly ten years at 3M, where he was most recently president and GM of the company's medical solutions division. Previously, Dr. Fruchterman spent five years as EVP at Kinetic Concepts Inc. He also served in key roles at Johnson & Johnson, Schering-Plough, and Response Genetics. At 3M and KCI, Dr. Fruchterman was both CTO and CMO. Most recently, he was Flex’s group president of reliability solutions.
 
"We are very excited Todd has joined Butterfly as president and CEO to lead the company at this critical stage. Todd brings together his unique qualifications and experience as an M.D., Ph.D. and proven business executive in public medical device companies, where he has successfully scaled disruptive technologies throughout his entire career," said Dr. Jonathan Rothberg, Butterfly’s founder and Chairman, in a press release. "Our most valuable assets are the people of Butterfly who innovate and serve on a daily basis, and I am pleased to support Todd as he builds upon a culture of purpose, joy and empowerment for our team and impact for patients and caregivers."
 
"It is a privilege for me to join Butterfly at this pivotal time in its pioneering effort to deliver affordable imaging solutions to the world," added Dr. Fruchterman. "Together with the deep and skilled leadership team, and with the support of Jonathan and Larry, I look forward to empowering a full spectrum of medical professionals, worldwide, with Butterfly's technology to help millions of patients achieve better, more cost-effective outcomes, and maintain wellness."
 
In anticipation of the closing of the business combination, Butterfly and Longview have also nominated Directors for election to the Board of Directors of the combined company.  Joining Dr. Rothberg (Chair), Dr. Fruchterman (President and CEO) and Robbins are Dawn Carfora, VP of business planning and operations, Global Business Group at Facebook; John Hammergren, former Chairman and CEO of McKesson Corporation; Gianluca Pettiti, senior VP and president of specialty diagnostics at Thermo Fisher Scientific; and S. Louise Phanstiel, Chair of the Board of Directors at Myriad Genetics.
 
"I am grateful to these independent directors for supporting our movement to use Ultrasound-on-Chip technology to make safe diagnostic imaging more accessible, more affordable and more effective," commented Dr. Rothberg. "We expect that their deep skills and directly relevant experiences will bring to the company wisdom and insight across operational, strategic, cultural and fiduciary spheres."
 
"As we strive to build a world-class global organization, we are fortunate to have the opportunity to access the perspectives and guidance of four highly accomplished executives whose current or prior employers—Anthem (Wellpoint), Facebook, McKesson, and Thermo Fisher Scientific—are all significant and admired growth companies," said Robbins. "We welcome them each as new Board members of the combined company and new investors in Butterfly."
 
Butterfly and Longview express their appreciation and best wishes to Laurent Faracci, Butterfly's former CEO who stepped down over the weekend. "Laurent recognized the value of this transformative combination and was critical in moving the company toward this goal and providing a seamless transition for the next phases of growth," said Dr. Rothberg. "We wish him well in his future endeavors."